About Glycemicon
Glycemicon is a company based in Brugg (Switzerland) founded in 2012. It operates as a D2C, B2B, and B2C. Glycemicon has raised $5.28 million across 3 funding rounds from investors including Venture Kick. Glycemicon offers products and services including Nitroethane, 2-Bromo 4-methylpropiophenone, Benzaldehyde, T Connectors, and Y Connectors. Glycemicon operates in a competitive market with competitors including Sana Biotechnology, Kriya Therapeutics, Semma Therapeutics, Cellino and Adocia, among others.
- Headquarter Brugg, Switzerland
-
Sectors
Industrial Goods & ManufacturingChemicals & Materials
-
Phone
Locked
-
Website
Locked
- Legal Name Webster Inc S.R.O.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$5.28 M (USD)
in 3 rounds
-
Latest Funding Round
$1.88 M (USD), Series A
Apr 05, 2018
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Glycemicon
Glycemicon offers a comprehensive portfolio of products and services, including Nitroethane, 2-Bromo 4-methylpropiophenone, Benzaldehyde, T Connectors, and Y Connectors.
Organic solvent for reactions and syntheses in chemical processes.
Intermediate used in pharmaceutical and industrial manufacturing.
Aromatic aldehyde for flavoring and chemical synthesis applications.
Polypropylene connectors for tubing in lab experiments and setups.
Barbed fittings for secure tubing connections in scientific work.
Funding Insights of Glycemicon
Glycemicon has successfully raised a total of $5.28M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $1.88 million completed in April 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Glycemicon
Glycemicon has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Venture Kick.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
University backed startup accelerator
|
Locked | Locked | Locked |
Investor details for Glycemicon
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Glycemicon
Investment portfolio details for Glycemicon
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Glycemicon
Detailed financials for Glycemicon
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Glycemicon Comparisons
Peer comparison for Glycemicon
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Glycemicon
Glycemicon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sana Biotechnology, Kriya Therapeutics, Semma Therapeutics, Cellino and Adocia, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| Locked | Locked | Locked |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment
|
|
| Locked | Locked | Locked |
Developer of autologous cell therapies
|
|
| Locked | Locked | Locked |
Therapeutics for diabetes and obesity treatment are developed.
|
|
| Locked | Locked | Locked |
Pendulum is focused on developing advanced probiotic solutions.
|
Detailed competitors of Glycemicon
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Glycemicon
Complete news archive for Glycemicon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Glycemicon
Glycemicon was founded in 2012 and raised its 1st funding round 1 year after it was founded.
Glycemicon is headquartered in Brugg, Switzerland. It is registered at Brugg, Aargau, Switzerland.
Glycemicon is a funded company, having raised a total of $5.28M across 3 funding rounds to date.
Glycemicon operates as an online chemical store, providing a variety of chemicals, laboratory glassware, and supplies to individuals and companies. Based in the Czech Republic, they ensure products are thoroughly checked and safely delivered globally. They accept Bitcoin payments and focus on high-quality items for research and industrial use, shipping to countries like the US, EU, and Asia.
Glycemicon's top competitors include Sana Biotechnology, Semma Therapeutics and Adocia.
Glycemicon offers Nitroethane, 2-Bromo 4-methylpropiophenone, Benzaldehyde, T Connectors, and Y Connectors.
Glycemicon has 1 investor. Key investors include Venture Kick.